Treatment interruptions and inconsistent supply of anti-tuberculosis drugs in the United Kingdom

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 6, 2011, Pages

  Capstick, Toby G D ^a   Laycock, D ^b   Lipman, M C I ^c  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b All Party Parliamentary Group on Global Tuberculosis   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Drugs; Essential; Health resources; Tuberculosis; United Kingdom

Indexed keywords

CYCLOSERINE; ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; RIFATER; TUBERCULOSTATIC AGENT;

ARTICLE; CROSS-SECTIONAL STUDY; DRUG FORMULATION; DRUG SHORTAGE; HEALTH CARE AVAILABILITY; HEALTH CARE PERSONNEL; HUMAN; LUNG TUBERCULOSIS; NATIONAL HEALTH SERVICE; PATIENT CARE; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED KINGDOM;

ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; DRUG INDUSTRY; GREAT BRITAIN; HUMANS; PEDIATRICS; PHARMACISTS; QUESTIONNAIRES; STATE MEDICINE; TUBERCULOSIS;

EID: 79955861259     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0568     Document Type: Article

References (21)

1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. WHO/HTM/TB/2009.411. Geneva, Switzerland: WHO, 2009. http://www.who.int/tb/publications/global-report/2009/pdf/full- report.pdf Accessed January 2010.
2. Health Protection Agency. Tuberculosis in the UK: annual report on tuberculosis surveillance in the UK 2009. London: HPA Centre for Infections, December 2009. http://www.hpa.org.uk/web/HPAwebFile/HPAweb-C/1259152022594 Accessed March 2011.
3. World Health Organization. WHO model list of essential medicines. 15th ed. Geneva, Switzerland: WHO, 2007. http://www.who.int/entity/medicines/ publications/08-ENGLISH-i ndexFINAL-EML15.pdf Accessed March 2011.
4. World Health Organization. The Stop TB Strategy. Building on and enhancing DOTS to meet the TB-related Millennium Development Goals. WHO/HTM/TB/2006.368. Geneva, Switzerland: WHO, 2006. http://whqlibdoc.who.int/ hq/2006/WHO-HTM-STB-2006.368-eng.pdf Accessed March 2011.
5. Kumaresan J, Smith I, Arnold V, Evans P. The Global TB Drug Facility: innovative global procurement. Int J Tuberc Lung Dis 2004; 8: 130-138. (Pubitemid 38120717)
6. National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, UK: NICE, 2006. www.nice.org.uk
7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008. http://whqlibdoc.who.int/publications/2008/ 9789241547581-eng.pdf Accessed March 2011.
8. World Health Organization. Prospectus: global TB drug facility. A global mechanism to ensure uninterrupted access to quality TB drugs for DOTS implementation. WHO/CDS/STB/2001.10a. Geneva, Switzerland: WHO, 2001. http://www.stoptb.org/assets/documents/gdf/whatis/GDF-Prospectus.PDF Accessed March 2011.
9. Rusen I D, Harries A D, Heldal E, Macé C. Drug supply shortages in 2010: the inexcusable failure of global tuberculosis control. Int J Tuberc Lung Dis 2010; 14: 253-254.
10. Department of Health. Stopping tuberculosis in England: an action plan from the Chief Medical Officer. London, UK: DH, 2004. http://www.dh.gov.uk/prod- consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-4100860.pdf Accessed March 2011.
11. Department of Health. Supply of TB drugs to patients - changes to regulations and advice on implementation. London, UK: DH, 2007. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Publichealth/ Communicablediseases/Tuberculosis/ DH-078136 Accessed October 2010.
12. National Patient Safety Agency. Review of patient safety for children and young people. National Reporting and Learning Service. London, UK: NPSA, June 2009. http://www.npsa.nhs.uk/EasySiteWeb/GatewayLink.aspx?alId=45187 Accessed March 2011.
13. National Patient Safety Agency. Safety in doses: medication safety incidents in the NHS. National Reporting and Learning Service. London, UK: NPSA, 2009. http://www.nrls.npsa.nhs.uk/EasySiteWeb/getresource.axd?AssetID= 61626&type=full &servicetype=Attachment%20report Accessed October 2010.
14. Jackson M N, Lowey A R, eds. Handbook of extemporaneous preparation: a guide to pharmaceutical compounding. London, UK: Pharmaceutical Press, 2010.
15. Wong I C K, Wong L Y L, Cranswick N E. Minimising medication errors in children. Arch Dis Child 2009; 94: 161-164.
16. Ahmed R Y, Capstick T G D, Watson J P. Outcomes and cost of MDR-TB in Leeds, 1996-2009. Thorax 2009; 64 (Suppl IV): A11.
17. Lowey A R, Jackson M N. A survey of extemporaneous preparation in NHS trusts in Yorkshire, the North-East and London. Hospital Pharmacist 2008; 15: 217-219. (Pubitemid 351872853)
18. British Pharmacopoeia (2007) Volume 1: 806. London, UK: The Stationery Office, 2007.
19. American Society of Health System Pharmacists Council on Administrative Affairs. ASHP guidelines on managing drug product shortages. Am J Health-Syst Pharm 2001; 58: 1445-1450.
20. Solutions: UK national NHS shortages database. London, UK: University College London Hospitals NHS Trust. http://www.uclhsolutions.com/index.asp Accessed March 2011.
21. Martin J, ed. British national formulary. No. 58, September 2009. The British Medical Association and the Royal Pharmaceutical Society of Great Britain. www.bnf.org